Literature DB >> 24434717

Estimation of ligand affinity constants for receptor states in functional studies involving the allosteric modulation of G protein-coupled receptors: implications for ligand bias.

Frederick J Ehlert1, Michael T Griffin2.   

Abstract

INTRODUCTION: The affinity constants of a ligand for active and inactive states of a receptor ultimately determine its capacity to activate downstream signaling events. In this report, we describe a reverse-engineering strategy for estimating these microscopic constants.
METHODS: Our approach involves analyzing responses measured downstream in the signaling pathway of a G protein-coupled receptor under conditions of allosteric modulation and reduced receptor expression or partial receptor inactivation. The analysis also yields estimates of the isomerization constant of the unoccupied receptor, the sensitivity constant of the signaling pathway, and the more empirical parameters of the receptor population including the observed affinities and efficacies of allosteric and orthosteric ligands - including inverse agonists - and the efficacy of the unoccupied receptor (i.e., constitutive activity). RESULTS AND DISCUSSION: We validate our approach with an analytical proof and by analysis of simulated data. We also use our method to analyze data from the literature. We show that the values of the microscopic constants of orthosteric and allosteric ligands are constant regardless of the allosteric interaction and the nature of the receptor-signaling pathway as long as the same active state mediates the response. Our analysis is useful for quantifying probe-dependent allosteric interactions and the selectivity of agonists for different signaling pathways. Knowing the isomerization constant and sensitivity constant of a signaling pathway in a given cell line or tissue preparation enables future investigators to estimate the affinity constants of agonists for receptor states simply through analysis of their concentration-response curves. Our approach also provides a means of validating in silico estimates of ligand affinity for crystal structures of active and inactive states of the receptor.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Affinity modulation; Agonist-bias; Allosterism; Constitutive activity; Efficacy modulation; Ligand-bias; Monod-Wyman-Changeux; Muscarinic receptor; Probe-dependence; Receptor states

Mesh:

Substances:

Year:  2014        PMID: 24434717      PMCID: PMC4028174          DOI: 10.1016/j.vascn.2014.01.002

Source DB:  PubMed          Journal:  J Pharmacol Toxicol Methods        ISSN: 1056-8719            Impact factor:   1.950


  44 in total

1.  Activation of muscle nicotinic acetylcholine receptor channels by nicotinic and muscarinic agonists.

Authors:  G Akk; A Auerbach
Journal:  Br J Pharmacol       Date:  1999-12       Impact factor: 8.739

2.  Guanine nucleotides differentiate agonist and antagonist interactions with opiate receptors.

Authors:  S R Childers; S H Snyder
Journal:  Life Sci       Date:  1978-08-21       Impact factor: 5.037

3.  Structural basis for modulation of a G-protein-coupled receptor by allosteric drugs.

Authors:  Ron O Dror; Hillary F Green; Celine Valant; David W Borhani; James R Valcourt; Albert C Pan; Daniel H Arlow; Meritxell Canals; J Robert Lane; Raphaël Rahmani; Jonathan B Baell; Patrick M Sexton; Arthur Christopoulos; David E Shaw
Journal:  Nature       Date:  2013-10-13       Impact factor: 49.962

4.  Guanine nucleotides modulate muscarinic receptor binding in the heart.

Authors:  C P Berrie; N J Birdsall; A S Burgen; E C Hulme
Journal:  Biochem Biophys Res Commun       Date:  1979-04-27       Impact factor: 3.575

5.  Operational models of pharmacological agonism.

Authors:  J W Black; P Leff
Journal:  Proc R Soc Lond B Biol Sci       Date:  1983-12-22

6.  On the stochastic properties of bursts of single ion channel openings and of clusters of bursts.

Authors:  D Colquhoun; A G Hawkes
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1982-12-24       Impact factor: 6.237

7.  Permeability control by cholinergic receptors in Torpedo postsynaptic membranes: agonist dose-response relations measured at second and millisecond times.

Authors:  R R Neubig; J B Cohen
Journal:  Biochemistry       Date:  1980-06-10       Impact factor: 3.162

8.  The relationship between muscarinic receptor occupancy and adenylate cyclase inhibition in the rabbit myocardium.

Authors:  F J Ehlert
Journal:  Mol Pharmacol       Date:  1985-11       Impact factor: 4.436

9.  Effect of guanine nucleotides on dopaminergic agonist and antagonist affinity for [3H]sulpiride binding sites in rat striatal membrane preparations.

Authors:  S B Freedman; J A Poat; G N Woodruff
Journal:  J Neurochem       Date:  1981-09       Impact factor: 5.372

10.  Coupling of muscarinic receptors to adenylate cyclase in the rabbit myocardium: effects of receptor inactivation.

Authors:  F J Ehlert
Journal:  J Pharmacol Exp Ther       Date:  1987-01       Impact factor: 4.030

View more
  4 in total

Review 1.  Practical Strategies and Concepts in GPCR Allosteric Modulator Discovery: Recent Advances with Metabotropic Glutamate Receptors.

Authors:  Craig W Lindsley; Kyle A Emmitte; Corey R Hopkins; Thomas M Bridges; Karen J Gregory; Colleen M Niswender; P Jeffrey Conn
Journal:  Chem Rev       Date:  2016-02-16       Impact factor: 60.622

Review 2.  Functional studies cast light on receptor states.

Authors:  Frederick J Ehlert
Journal:  Trends Pharmacol Sci       Date:  2015-06-26       Impact factor: 14.819

3.  Estimation of the receptor-state affinity constants of ligands in functional studies using wild type and constitutively active mutant receptors: Implications for estimation of agonist bias.

Authors:  Frederick J Ehlert; Richard S L Stein
Journal:  J Pharmacol Toxicol Methods       Date:  2016-10-07       Impact factor: 1.950

4.  Quantitative Measure of Receptor Agonist and Modulator Equi-Response and Equi-Occupancy Selectivity.

Authors:  Rumin Zhang; Michael Kavana
Journal:  Sci Rep       Date:  2016-04-27       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.